Roche/DeCode Genetics $200 mil. genomics deal to use Icelandic population data.

ROCHE/DECODE GENOMICS DEAL TO FOCUS ON SCHIZOPHRENIA, DIABETES and 10 other diseases under an agreement announced by the companies Feb. 2. The five-year deal, which is valued at over $200 mil., is being heralded by the firms as "the largest human genomics deal ever." The initial focus of the collaboration is understood to be on a group of six diseases including adult onset diabetes and schizophrenia, with another group of six being researched at a secondary level. The agreement will cover four cardiovascular diseases, four psychiatric/neurologic disorders and four metabolic diseases.